Link to this page
Biological and Environmental Research Ontology
| Preferred Name | Pembrolizumab | |
| Synonyms |
|
|
| Definitions |
A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C106432 |
|
| Accepted_Therapeutic_Use_For |
soft tissue sarcoma (STS) postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer; recurrent or metastatic head and neck squamous cell carcinoma (HNSCC); metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1; unresectable or metastatic melanoma or melanoma with involvement of lymph node(s) following complete resection; metastatic small cell lung cancer (SCLC); advanced renal cell carcinoma (RCC); recurrent or metastatic cervical cancer; refractory primary mediastinal large B-cell lymphoma (PMBCL); urothelial cancer; hepatocellular carcinoma (HCC); recurrent locally advanced or metastatic Merkel cell carcinoma (MCC)
|
|
| CAS_Registry |
1374853-91-4
|
|
| code |
C106432
|
|
| Contributing_Source |
CTRP FDA PCDC
|
|
| definition |
A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.
|
|
| Display_Name |
Pembrolizumab
|
|
| FDA_UNII_Code |
DPT0O3T46P
|
|
| Has_Target | ||
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C173383 http://purl.obolibrary.org/obo/NCIT_C173381 http://purl.obolibrary.org/obo/NCIT_C186341 http://purl.obolibrary.org/obo/NCIT_C177537 http://purl.obolibrary.org/obo/NCIT_C176424 http://purl.obolibrary.org/obo/NCIT_C116977 http://purl.obolibrary.org/obo/NCIT_C116978 http://purl.obolibrary.org/obo/NCIT_C128784 http://purl.obolibrary.org/obo/NCIT_C186327 http://purl.obolibrary.org/obo/NCIT_C186328 |
|
| Is_Value_For_GDC_Property | ||
| label |
Pembrolizumab
|
|
| Maps_To |
Pembrolizumab
|
|
| NCI_Drug_Dictionary_ID |
695789
|
|
| PDQ_Closed_Trial_Search_ID |
695789
|
|
| PDQ_Open_Trial_Search_ID |
695789
|
|
| Preferred_Name |
Pembrolizumab
|
|
| prefixIRI |
NCIT:C106432
|
|
| prefLabel |
Pembrolizumab
|
|
| Semantic_Type |
Amino Acid, Peptide, or Protein Pharmacologic Substance
|
|
| UMLS_CUI |
C3658706
|
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |